Loan & DebtMay 26, 2026, 07:12 AM
Cartesian Therapeutics Secures up to $150M Non-Dilutive Financing
AI Summary
Cartesian Therapeutics, Inc. secured a Loan and Security Agreement for up to $150.0 million from K2 HealthVentures, with an initial $50.0 million tranche funded. This financing is expected to extend the company's cash runway into 2028 and support the advancement of multiple clinical programs. The company also provided updated timelines for its Descartes-08 clinical trials, including Phase 3 AURORA data in 1Q27, Phase 2 TRITON data in 1H27, and Phase 1/2 HELIOS data in 1H27. Additionally, the Chief Medical Officer, Miloš Miljković, will step down for personal reasons.
Key Highlights
- Secured up to $150.0 million in senior secured term loans from K2 HealthVentures.
- Initial tranche of $50.0 million funded, extending cash runway into 2028.
- Second tranche of $25.0 million available between January 1, 2027 and December 1, 2027, subject to milestones.
- Third tranche of $25.0 million available between January 1, 2028 and June 1, 2028, subject to milestones.
- Lenders may convert up to $15.0 million of outstanding principal into common stock at $8.2526 per share.
- Topline data from Phase 3 AURORA trial in myasthenia gravis expected in 1Q27.
- Data from Phase 2 TRITON trial in myositis expected in 1H27.
- Chief Medical Officer Miloš Miljković will step down for personal reasons.
Price Impact
More from RNAC